Hims & Hers Health (NYSE:HIMS) Shares Down 0.1%

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) traded down 0.1% during mid-day trading on Tuesday . The stock traded as low as $21.03 and last traded at $21.40. 1,558,055 shares changed hands during trading, a decline of 79% from the average session volume of 7,468,674 shares. The stock had previously closed at $21.42.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HIMS. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Canaccord Genuity Group assumed coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Jefferies Financial Group increased their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Finally, Bank of America lifted their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Hims & Hers Health Price Performance

The stock has a market capitalization of $4.40 billion, a PE ratio of -2,047.00 and a beta of 1.08. The company has a 50 day moving average price of $18.12 and a 200-day moving average price of $13.78.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter in the previous year, the business posted ($0.05) earnings per share. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,502 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total value of $43,359.66. Following the completion of the transaction, the insider now owns 156,855 shares in the company, valued at approximately $2,718,297.15. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Hims & Hers Health news, COO Melissa Baird sold 11,750 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the completion of the transaction, the chief operating officer now owns 538,932 shares of the company’s stock, valued at $6,510,298.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,502 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $17.33, for a total transaction of $43,359.66. Following the transaction, the insider now owns 156,855 shares of the company’s stock, valued at $2,718,297.15. The disclosure for this sale can be found here. Insiders sold 771,400 shares of company stock worth $14,063,900 over the last three months. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cetera Advisors LLC bought a new stake in Hims & Hers Health in the first quarter worth $396,000. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. Virtu Financial LLC bought a new position in Hims & Hers Health in the 1st quarter worth about $638,000. Strategic Wealth Partners Ltd. purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $839,000. Finally, Bayesian Capital Management LP purchased a new stake in Hims & Hers Health during the 1st quarter valued at about $1,770,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.